Mechanistic concepts in androgen-dependence of prostate cancer.
Androgen blockade is the mainstay of therapy in the clinical management of advanced prostate cancer. Recent progress on two fronts--the development of newer xenograft and transgenic models and a greater understanding of nuclear receptor signaling--has provided new insight into mechanisms of androgen-dependence in prostate cancer. This review centers on the concept that perturbations in androgen receptor signaling are likely to occur early in prostate cancer and play a critical role in progression to end stage hormone-refractory disease.
Craft
N
N
Department of Medicine, University of California, Los Angeles, USA.
Sawyers
C L
CL
D000728:Androgens / Q000378:metabolism* / Q000502:physiology; D017209:Apoptosis; D002455:Cell Division / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000145:classification / Q000378:metabolism* / Q000473:pathology; D011944:Receptors, Androgen / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D015534:Trans-Activators / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism
D000728:Androgens; D011944:Receptors, Androgen; D018160:Receptors, Cytoplasmic and Nuclear; D015534:Trans-Activators; D014157:Transcription Factors